FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | GlaxoSmithKline | FDA approval

GSK prevails in Paxil suicide suit

Tools

Pre-emption handed GlaxoSmithKline the victory in a lawsuit over a 13-year-old who committed suicide while taking the antidepressant Paxil. A California judge cited the pre-emption rule in dismissing the suit, saying that the case created a direct conflict between federal labeling requirements and state tort law. Glaxo couldn't have complied with both, the judge said, and federal law pre-empts state law--so out with the suit.

The thing is, this ruling could not only set a precedent, causing all sorts of damage suits against drug companies to get tossed, but might be a harbinger of an even bigger precedent-setter. The Supreme Court is set to consider a couple of cases that rest on this notion of pre-emption. As the reasoning goes (greatly simplified; I'm no lawyer) the federal government vested FDA with the power to regulate drugs and devices, so FDA approval should shield drugs and devices from state liability.

- check out the coverage from Pharmalot

Related Articles:
UK patients sue for Paxil withdrawal. Report
Study highlights link between Paxil and suicide. Report
Glaxo to let Mylan make generic Paxil. Report
Study: Antidepressant warnings work. Report

More stories about FDA   GlaxoSmithKline   FDA approval  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.